Zydus Lifesciences Shares Dip on USFDA Observations at Gujarat Plant

HEALTHCAREBIOTECH

Overview

Zydus Lifesciences shares are under scrutiny after its Gujarat manufacturing unit received three observations from the US Food and Drug Administration. The inspection concluded January 23, 2026. Importantly, the company clarified that no data integrity issues were identified, and it plans to address the observations expeditiously.

The USFDA inspection of Zydus Lifesciences' Unit-2 manufacturing facility in Ankleshwar, Gujarat, concluded on January 23, 2026, yielding three distinct observations. The inspection period spanned from January 19 to January 23, 2026.

Company Response and Data Integrity

Zydus Lifesciences moved quickly to address market concerns, stating that no data-integrity related observations were issued by the US regulator. The pharmaceutical firm assured stakeholders that it would work closely with the USFDA to resolve the noted observations promptly.

Recent Business Developments

This regulatory update comes shortly after Zydus Lifesciences launched the world's first biosimilar of Nivolumab in India last week, branded as Tishtha. The drug is available in 100 mg and 40 mg dosages, priced at Rs 28,950 and Rs 13,950, respectively.

Stock Performance Analysis

In the preceding trading session, Zydus Lifesciences shares closed at Rs 881.95, marking a 0.33% decline. The stock has previously touched a 52-week high of Rs 1,059.00 on September 19, 2025, and a 52-week low of Rs 797.05 on April 07, 2025. Currently, the stock trades 16.72% below its peak and 10.65% above its lowest point. The company's market capitalization stands at Rs 88,744.81 crore.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.